H.I.G. Capital raises $268M for new bioventures fund
This article was originally published in Scrip
H.I.G. Capital, a global private equity firm with more than $8.5 billion under management, has closed its second life sciences-focused venture fund - H.I.G. BioVentures II – at $268 million, exceeding its $250 million target. Like its first life sciences fund, HIG BioVentures, the new fund will invest in North American companies across a broad range of sectors and development stages, with a focus on pharmaceuticals, medical devices, and diagnostics.